Mounjaro®
Starting from £179.99/mo
Start journey Learn moreTaking semaglutide twice in a single week means doubling your intended weekly dose, and that matters clinically. Semaglutide — the active medicine in Wegovy — is licensed strictly as a once-weekly injection. An accidental or deliberate double dose does not accelerate weight loss; it significantly increases the likelihood of side effects, particularly nausea, vomiting, and other gastrointestinal symptoms, and in some circumstances may require medical attention. These are prescription-only medicines for a reason: the dosing schedule exists because of how long semaglutide stays active in the body, not as an arbitrary rule. If you realise you have taken Wegovy twice this week, the guidance below explains what typically happens, what to watch for, and when to call for help. Clinical decisions about your own treatment always rest with your prescriber, not a webpage.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Semaglutide is designed to be a long-acting GLP-1 receptor agonist. Its half-life sits at around seven days, which means a meaningful amount of the previous week's dose is still circulating when the next injection is due. That extended action is precisely why once-weekly dosing produces steady blood levels and consistent appetite reduction over time.
When a second dose arrives before the first has cleared, plasma levels rise well above what the medicine's clinical trials targeted. The GLP-1 pathway then drives gastric emptying to slow further and appetite signals to suppress more intensely than intended. For many people that translates directly into stronger nausea, vomiting, diarrhoea, or reflux. These effects are not a sign the medicine is working better, they are the body flagging that levels are higher than planned. The NHS medicine page for semaglutide explains the common gastrointestinal side-effect profile in detail.
Dehydration is a real secondary risk if vomiting or diarrhoea is prolonged. In vulnerable people this can affect kidney function. There is also no mechanism by which a double dose shortens the time to reaching your maintenance dose safely, the titration schedule in Wegovy exists to let your system adapt at each level, and compressing it creates discomfort without clinical benefit. If you have ever found yourself asking whether it is safe to inject semaglutide twice a week, the honest answer from the clinical data is no, and the same reasoning applies to Wegovy: if you have ever wondered whether injecting Wegovy twice a week could speed results, the honest answer from the clinical data is no.
Symptoms, if they come, tend to begin within a few hours of the second injection. Nausea is the most common report. It may be mild and self-limiting, or it may be intense enough to prevent eating or drinking normally. Vomiting, loose stools, stomach cramps, and fatigue are all plausible. Most people who take a single accidental extra dose will feel rough for a day or two and then recover as levels begin to fall.
The practical check you can do right now: look at the date and time stamps in your injection diary, or on your pen packaging if you noted it, and confirm whether this really is a double dose or whether you have simply lost track of the day. Semaglutide pens are not re-usable between injections in the same week, so checking the cap and dose window takes under a minute. If you are uncertain, that uncertainty itself is worth raising with your prescriber.
More serious symptoms warrant prompt help. Severe, persistent abdominal pain (especially pain that spreads to the back) is something the MHRA flagged specifically in a 2026 Drug Safety Update on GLP-1 medicines as a reason to seek urgent care, given the association with acute pancreatitis. Signs of significant dehydration (dizziness on standing, very dark urine, inability to keep fluids down for several hours) also need medical assessment. You can read more about the broader effects of taking too much semaglutide in our dedicated guidance.
Contact your prescriber or call NHS 111 if you are unsure. Do not rely on general information to decide whether to skip the following week's injection, adjust timing, or take a different dose. Those are clinical decisions that depend on when exactly the extra injection was given, how you are feeling, and your full medical picture.
As a general principle, the prescribing guidance for Wegovy does not recommend giving an extra injection to compensate for a missed one either, the approach is to return to the regular schedule as soon as practical. The logic works in both directions: taking semaglutide a day early carries similar scheduling questions, and the advice is consistent: your prescriber and the Patient Information Leaflet are the authoritative sources for your specific situation.
One practical note on pens: Wegovy pens come pre-filled, and each contains a single set dose. They are not adjustable. If you are curious about whether Wegovy pens can be dialled to a different dose, the answer is no, which also means the risk of accidentally delivering a partial extra dose is low, but accidentally using a second pen in one week is a real scenario worth guarding against.
If you are thinking about whether Wegovy or another weight-loss treatment is the right route for you, our prescribers can talk through the full picture. Treatment is a prescription-only process, and the starting place is always a clinical assessment rather than a dosing question answered online. Check your eligibility with a free consultation and have those questions answered properly.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.